Published: International Journal of Obesity
Authors: R H Lustig 1 , F Greenway, P Velasquez-Mieyer, D Heimburger, D Schumacher, D Smith, W Smith, N Soler, G Warsi, W Berg, J Maloney, J Benedetto, W Zhu, J Hohneker
To compare changes in weight in obese patients who received long-acting octreotide (octreotide LAR) at one of three dose levels (20, 40, or 60 mg) or placebo over 6 months and to identify the lowest dose of octreotide LAR that safely achieved optimal weight loss.